Literature DB >> 2663614

Ovarian carcinoma as a cause of Zollinger-Ellison syndrome. Natural history, secretory products, and response to provocative tests.

P N Maton1, S M Mackem, J A Norton, J D Gardner, T M O'Dorisio, R T Jensen.   

Abstract

Zollinger-Ellison syndrome is usually caused by a gastrin-secreting tumor in or near the pancreas. We describe a patient in whom an ovarian cystadenocarcinoma was the cause of the syndrome. The patient presented with a short history of peptic ulceration and development of a large pelvic mass. Investigations demonstrated a basal acid output of 37.8 mEq/h and a maximal acid output of 36.0 mEq/h, and the plasma concentration of gastrin was 830 pg/ml (normal less than 100). Secretin and calcium infusion tests were positive, and a meal test was compatible with Zollinger-Ellison syndrome. Imaging studies demonstrated a normal liver and pancreas but a large cystic right ovarian mass. Resection of the mass resulted in a marked reduction in gastric acid output, a fall in plasma gastrin concentration to normal, negative calcium and secretin tests, and a normal (positive) meal test. Histology of the mass showed it to be a mucinous cystadenocarcinoma. The tumor stained with immunoperoxidase technique was positive for gastrin, and the cyst fluid contained high concentrations of gastrin and calcitonin. One year later, the patient has no biochemical or imaging evidence of tumor. Ovarian, gastrin-producing tumors and pancreatic gastrinomas cannot be distinguished by provocative tests, and negative imaging studies do not exclude a pancreatic tumor. Patients with an ovarian mass and Zollinger-Ellison syndrome should have a bilateral oophorectomy and a careful exploration of the pancreatic area.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2663614     DOI: 10.1016/0016-5085(89)90085-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

Review 1.  Gastrinomas: Medical or Surgical Treatment.

Authors:  Jeffrey A Norton; Deshka S Foster; Tetsuhide Ito; Robert T Jensen
Journal:  Endocrinol Metab Clin North Am       Date:  2018-09       Impact factor: 4.741

2.  Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract.

Authors:  Jeffrey A. Norton; Deshka S. Foster; Leslie H. Blumgart; George A. Poultsides; Brendan C. Visser; Douglas L. Fraker; H. Richard Alexander; Robert T. Jensen
Journal:  JAMA Surg       Date:  2018-03-01       Impact factor: 14.766

3.  Primary hepatic gastrinoma: Report of a case and review of literature.

Authors:  Konstantinos Tsalis; Georgios Vrakas; Stergios Vradelis; Abraham Dimoulas; Maria Pilavaki; Stiliani Papaemmanouil; Anastasia Micheli; Charalampos Lazarides; Georgios Kartalis
Journal:  World J Gastrointest Pathophysiol       Date:  2011-04-15

Review 4.  Hormone-producing tumors of the ovary.

Authors:  Ara Chalvardjian
Journal:  Endocr Pathol       Date:  1990-09       Impact factor: 3.943

5.  Aberrant hormone production from ovarian neoplasms: strategies for diagnosis and therapy.

Authors:  S D Leach; A I LaMorte; L D True; S D Flynn; P E Schwartz; C E Cahow; B K Kinder
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

6.  Gastrinomas: a 42-year experience.

Authors:  E L Kaplan; K Horvath; A Udekwu; F Straus; C Schark; D J Ferguson; D B Skinner
Journal:  World J Surg       Date:  1990 May-Jun       Impact factor: 3.352

Review 7.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

Review 8.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.